Naples Money Management LLC Buys Shares of 441 Eli Lilly and Company (NYSE:LLY)

Naples Money Management LLC purchased a new stake in Eli Lilly and Company (NYSE:LLY) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 441 shares of the company’s stock, valued at approximately $257,000.

Other large investors have also recently made changes to their positions in the company. Fairfield Bush & CO. purchased a new position in Eli Lilly and Company in the first quarter valued at about $107,000. Roundview Capital LLC grew its position in shares of Eli Lilly and Company by 2.6% in the 1st quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock worth $589,000 after buying an additional 53 shares during the last quarter. Merit Financial Group LLC bought a new position in shares of Eli Lilly and Company during the 1st quarter worth approximately $210,000. NewEdge Advisors LLC lifted its position in Eli Lilly and Company by 9.9% during the first quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock valued at $15,193,000 after acquiring an additional 4,774 shares during the last quarter. Finally, Barometer Capital Management Inc. acquired a new stake in Eli Lilly and Company in the first quarter valued at approximately $561,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded down $19.64 during midday trading on Friday, reaching $726.31. 3,486,055 shares of the stock were exchanged, compared to its average volume of 3,073,465. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The firm has a market cap of $690.11 billion, a price-to-earnings ratio of 125.67, a PEG ratio of 1.64 and a beta of 0.34. The firm has a 50-day simple moving average of $764.24 and a two-hundred day simple moving average of $658.28. Eli Lilly and Company has a twelve month low of $369.76 and a twelve month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the prior year, the firm posted $2.09 earnings per share. The firm’s quarterly revenue was up 28.1% compared to the same quarter last year. As a group, analysts anticipate that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. BMO Capital Markets boosted their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Bank of America boosted their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $815.00 price objective on shares of Eli Lilly and Company in a report on Monday. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $728.05.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.